GENOSOPHY® is committed to advancing personalized prevention and early disease detection through cutting-edge genomics. Our research integrates multi-omic analyses to reveal early molecular signatures, deciphers gene–environment interactions for precision lifestyle interventions, and validates novel biomarkers for minimally invasive diagnostics.
We also develop genomics-guided strategies to optimize human resilience and performance, while refining clinically actionable polygenic risk scores for complex diseases. Through these initiatives, GENOSOPHY® bridges innovative genomic science with real-world healthcare needs, contributing to the evolution of precision medicine and proactive health management.
Understanding gene–environment interactions is critical for optimizing health. GENOSOPHY® focuses on identifying functional genetic variants that influence metabolic fitness, bone strength, cardiovascular resilience, and aging, enabling the design of targeted nutritional, exercise, and behavioral interventions tailored to an individual’s unique genetic profile.
Recognizing the growing clinical relevance of polygenic scores, GENOSOPHY® invests in refining polygenic risk models for diseases such as osteoporosis, cardiovascular disorders, cancer and metabolic diseases. Our approach emphasizes diverse populations, clinical validation, and actionable translation to inform individualized prevention and early therapeutic strategies.
Applying genetic insights, GENOSOPHY® develops personalized protocols to enhance physical endurance, cognitive resilience, and stress adaptability. Our focus includes populations operating in extreme conditions — from military personnel to elite athletes — aiming to translate genomic science into tangible gains in human performance and operational readiness.
GENOSOPHY® advances the integration of single-cell omic technologies to detect early molecular signatures of disease. We deliver simultaneous single-cell RNAseq and ATACseq providing advanced genomic insights at the cellular level. We seek to enhance precision risk prediction, identify new biomarkers, and design proactive intervention strategies in chronic and degenerative conditions.
GENOSOPHY® is committed to discovering and clinically validating novel biomarkers, such as circulating DNA methylation profiles and non-coding RNA signatures, for early detection of complex diseases. Our goal is to shift the paradigm toward minimally invasive, genomics-driven preventive diagnostics before clinical symptoms arise.
| 1. | Eliopoulos AG, Gkouskou KK, Tsioufis K, Sanoudou D. A perspective on intermittent fasting and cardiovascular risk in the era of obesity pharmacotherapy. Front Nutr. 2025 Jan 17;12:1524125. doi: 10.3389/fnut.2025.1524125. |
| 2. | Vafiadaki E, Kranias EG, Eliopoulos AG, Sanoudou D. The phospholamban R14del generates pathogenic aggregates by impairing autophagosome-lysosome fusion. Cell Mol Life Sci. 2024 Nov 11;81(1):450. doi: 10.1007/s00018-024-05471-1. |
| 3. | Varveri A, Papadopoulou M, Papadovasilakis Z, Compeer EB, Legaki AI, Delis A, Damaskou V, Boon L, Papadogiorgaki S, Samiotaki M, Foukas PG, Eliopoulos AG, Hatzioannou A, Alissafi T, Dustin ML, Verginis P. Immunological synapse formation between T regulatory cells and cancer-associated fibroblasts promotes tumour development. Nat Commun. 2024 Jun 11;15(1):4988. doi: 10.1038/s41467-024-49282-1. |
| 4. | Veneti Z, Fasoulaki V, Kalavros N, Vlachos IS, Delidakis C, Eliopoulos AG. Polycomb-mediated silencing of miR-8 is required for maintenance of intestinal stemness in Drosophila melanogaster. Nat Commun. 2024 Mar 2;15(1):1924. doi: 10.1038/s41467-024-46119-9. |
| 5. | Gkouskou KK, Grammatikopoulou MG, Lazou E, Vasilogiannakopoulou T, Sanoudou D, Eliopoulos AG. A genomics perspective of personalized prevention and management of obesity. Hum Genomics. 2024 Jan 29;18(1):4. doi: 10.1186/s40246-024-00570-3. |
| 6. | Papadopoulos G, Legaki AI, Georgila K, Vorkas P, Giannousi E, Stamatakis G, Moustakas II, Petrocheilou M, Pyrina I, Gercken B, Kassi E, Chavakis T, Pateras IS, Panayotou G, Gika H, Samiotaki M, Eliopoulos AG, Chatzigeorgiou A. Integrated omics analysis for characterization of the contribution of high fructose corn syrup to non-alcoholic fatty liver disease in obesity. Metabolism. 2023 Jul;144:155552. doi: 10.1016/j.metabol.2023.155552. |
| 7. | Grammatikopoulou MG, Skoufas E, Kanellakis S, Sanoudou D, Pavlopoulos GA, Eliopoulos AG, Gkouskou KK. Ageotypes revisited: The brain and central nervous system dysfunction as a major nutritional and lifestyle target for healthy aging. Maturitas. 2023 Apr;170:51-57. doi: 10.1016/j.maturitas.2023.01.013. |
| 8. | Sanoudou D, Gkouskou KK, Eliopoulos AG, Mantzoros CS. Epitranscriptomic challenges and promises in metabolic diseases. Metabolism. 2022 Jul;132:155219. doi: 10.1016/j.metabol.2022.155219. |
| 9. | Stouras I, Papaioannou TG, Tsioufis K, Eliopoulos AG, Sanoudou D. The Challenge and Importance of Integrating Drug-Nutrient-Genome Interactions in Personalized Cardiovascular Healthcare. J Pers Med. 2022 Mar 22;12(4):513. doi: 10.3390/jpm12040513. |
| 10. | Karatzas E, Baltoumas FA, Kasionis I, Sanoudou D, Eliopoulos AG, Theodosiou T, Iliopoulos I, Pavlopoulos GA. Darling: A Web Application for Detecting Disease-Related Biomedical Entity Associations with Literature Mining. Biomolecules. 2022 Mar 30;12(4):520. doi: 10.3390/biom12040520. |
| 11. | Gkouskou KK, Grammatikopoulou MG, Lazou E, Sanoudou D, Goulis DG, Eliopoulos AG. Genetically-Guided Medical Nutrition Therapy in Type 2 Diabetes Mellitus and Pre-diabetes: A Series of n-of-1 Superiority Trials. Front Nutr. 2022 Feb 21;9:772243. doi: 10.3389/fnut.2022.772243. |
| 12. | Baltoumas FA, Zafeiropoulou S, Karatzas E, Paragkamian S, Thanati F, Iliopoulos I, Eliopoulos AG, Schneider R, Jensen LJ, Pafilis E, Pavlopoulos GA. OnTheFly2.0: a text-mining web application for automated biomedical entity recognition, document annotation, network and functional enrichment analysis. NAR Genom Bioinform. 2021 Oct 6;3(4):lqab090. doi: 10.1093/nargab/lqab090. |
| 13. | Gkouskou KK, Georgiopoulos G, Vlastos I, Lazou E, Chaniotis D, Papaioannou TG, Mantzoros CS, Sanoudou D, Eliopoulos AG. CYP1A2 polymorphisms modify the association of habitual coffee consumption with appetite, macronutrient intake, and body mass index: results from an observational cohort and a cross-over randomized study. Int J Obes (Lond). 2022 Jan;46(1):162-168. doi: 10.1038/s41366-021-00972-6. |
| 14. | Thanati F, Karatzas E, Baltoumas FA, Stravopodis DJ, Eliopoulos AG, Pavlopoulos GA. FLAME: A Web Tool for Functional and Literature Enrichment Analysis of Multiple Gene Lists. Biology (Basel). 2021 Jul 14;10(7):665. doi: 10.3390/biology10070665. |
| 15. | Gkouskou K, Vasilogiannakopoulou T, Andreakos E, Davanos N, Gazouli M, Sanoudou D, Eliopoulos AG. COVID-19 enters the expanding network of apolipoprotein E4-related pathologies. Redox Biol. 2021 May;41:101938. doi: 10.1016/j.redox.2021.101938. |
| 16. | Gkouskou K, Lazou E, Skoufas E, Eliopoulos AG. Genetically Guided Mediterranean Diet for the Personalized Nutritional Management of Type 2 Diabetes Mellitus. Nutrients. 2021 Jan 25;13(2):355. doi: 10.3390/nu13020355. |
| 17. | Vafiadaki E, Arvanitis DA, Eliopoulos AG, Kranias EG, Sanoudou D. The Cardioprotective PKA-Mediated Hsp20 Phosphorylation Modulates Protein Associations Regulating Cytoskeletal Dynamics. Int J Mol Sci. 2020 Dec 16;21(24):9572. doi: 10.3390/ijms21249572. |
